Hudson Bay Capital Management
VKTX icon

Hudson Bay Capital Management’s Viking Therapeutics VKTX Stock Holding History

Hudson Bay Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,089
Closed -$38.3K – 1614
2025
Q4 		$38.3K Buy
+1,089
New +$38.6K ﹤0.01% 1101
2023
Q4 		– Sell
-214,339
Closed -$2.37M – 904
2023
Q3 		$2.37M Buy
+214,339
New +$3.07M 0.02% 449
2023
Q2 		– Sell
-10,000
Closed -$167K – 977
2023
Q1 		$167K Buy
+10,000
New +$103K ﹤0.01% 657

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Hudson Bay Capital Management's VKTX Position: Q1 2026 in Review

Hudson Bay Capital Management sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 1,089 shares — an estimated $38.3K sold.

Hudson Bay Capital Management first reported a position in VKTX in Q1 2023 and held it in 3 quarters. The position peaked at $2.37M in Q3 2023. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • Hudson Bay Capital Management reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Hudson Bay Capital Management sold 1,089 Viking Therapeutics shares in Q1 2026, an estimated $38.3K.
  • Hudson Bay Capital Management first reported a position in Viking Therapeutics in Q1 2023 and held it in 3 quarters.
  • Hudson Bay Capital Management's Viking Therapeutics position peaked at $2.37M in Q3 2023.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Hudson Bay Capital Management's 13F filing for Q1 2026, filed 13 May 2026.